1. IN8bio secures $40.2 million through a private placement for INB-619. 2. Initial proceeds extend cash runway into the first half of 2027. 3. Funding will support IND studies for cancer and autoimmune diseases. 4. Potential additional funds depend on achieving preclinical milestones. 5. Investors include Coastlands Capital and other biotechnology partners.
FAQ
Why Bullish?
The financing enhances INAB's capital position, boosting investor confidence amidst its clinical developments, similar to past funding successes aiding biotech advancements.
How important is it?
The capital raise is crucial for ongoing clinical programs and presents an opportunity for long-term growth, enhancing IN8bio's strategic position in its sector.
Why Long Term?
With pivotal data expected in 2027, the private placement provides necessary funds for critical FDA interactions and project advancement.
IN8bio Announces Pricing of Private Placement of Up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company specializing in γδ T cell therapies, has announced a definitive agreement to secure approximately $40.2 million in gross proceeds through a private placement. This funding aims to support the development of their groundbreaking INB-619 γδ T cell engager via an Investigational New Drug (IND) application.
Details of the Financing Agreement
Under the terms of the securities purchase agreement (SPA), the initial closing will raise approximately $20.1 million in gross proceeds. At this closing, IN8bio plans to sell 5,127,029 shares of common stock at a price of $1.38 per share, alongside pre-funded warrants to purchase up to 9,452,677 shares at a price of $1.3799 each.
The initial tranche's proceeds will extend the company’s cash runway into the first half of 2027. Notably, INAB could secure an additional $20.1 million contingent on milestone-driven conditions related to preclinical data for INB-619 and stock performance.
- Initial funding: $20.1 million
- Additional potential funding: $20.1 million
- Share price: $1.38 per common share
- Expected cash runway until mid-2027
Strategic Use of Proceeds
IN8bio intends to allocate the net proceeds primarily for the IND-enabling studies of INB-619, focusing on applications in oncology and autoimmune diseases. The company anticipates generating preliminary preclinical data in 2026, followed by pivotal animal model data and an IND application in 2027.
Additionally, funds will be used to submit data from INB-200 and INB-400 Phase 1 and Phase 2 clinical programs, targeting newly diagnosed glioblastoma to the U.S. Food and Drug Administration (FDA).
Participant Insights and Future Plans
The financing round is backed by prominent investors, including Coastlands Capital, Stonepine Capital Management, and 683 Capital Partners, along with various directors and officers associated with IN8bio. H.C. Wainwright & Co. will serve as the exclusive placement agent for this private placement.
The anticipated closing date for the initial funding tranche is December 22, 2025, pending normal closing conditions. This strategic investment marks a crucial step as IN8bio advances its capabilities in the promising field of γδ T cell therapies.
About IN8bio
IN8bio is a forward-looking biopharmaceutical company developing γδ T cell therapies to meet significant medical demands. Their leading program, INB-100, targets acute myeloid leukemia using haplo-matched allogeneic γδ T cells post-hematopoietic stem cell transplant. Additionally, ongoing evaluations include autologous DeltEx DRI γδ T cells for glioblastoma through the INB-200 and INB-400 programs.
Forward-Looking Statements
This release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. This includes anticipated timelines for the private placement and plans to achieve crucial milestones or submit applications to the FDA. INAB investors are advised to exercise caution in relying on these statements, as actual outcomes may differ significantly due to various factors affecting the biotechnology market.